Skip to main content
Premium Trial:

Request an Annual Quote

Takeda Licenses CellCentric's Technologies

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Takeda Pharmaceutical Company has licensed from CellCentric cancer-related epigenetic target technologies for development and commercialization.

Under the agreement, Takeda's Research Group will conduct therapeutic research on molecules that will be further developed by Millenium, the biopharmaceutical firm that Takeda acquired in 2008.

The agreement includes an up-front payment, clinical and pre-clinical milestones, and royalties. Overall, the pact could reap as much as $200 million for CellCentric over the course of the agreement.

The CellCentric technology is based on epigenetic alterations caused by a range of enzymes that can be targeted and may be of use in cancer treatment, including histone methyltranserases, demethylases, and ubiquitin-related enzymes.

CellCentric CEO Will West said in a statement that epigenetics "is an area that is no longer seen as just interesting, but as a necessity for pharmaceutical companies growing their armory for tackling intractable diseases such as cancer."

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.